YK 0901
Alternative Names: YK-0901Latest Information Update: 25 Aug 2023
At a glance
- Originator Yingkai Saiwei (Beijing) Biotechnology
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 14 Jul 2023 Preclinical trials in Solid tumours in China (Parenteral)
- 06 Jul 2023 Yingkai SaiweiBeijingBiotechnology and Peking University plans a phase I trial for Solid tumours (Late-stage disease, Inoperable/Unresectable) in China (Parenteral) (NCT05933668)